公开(公告)号：US11085916B2

公开(公告)日：2021-08-10

申请号：US16085755

申请日：2017-07-18

Applicant: MANDOM CORPORATION ,  OSAKA UNIVERSITY

Inventor： Kie Nakashima ,  Ryuichiro Kurata ,  Fumitaka Fujita ,  Kiyotoshi Sekiguchi ,  Atsushi Tanemura ,  Hiroyuki Murota ,  Ichiro Katayama

IPC: G01N33/50 ,  A61B5/00 ,  A61K38/18

Abstract: A method for observing the dynamics of sweat glands and a method for evaluating a substance of interest, which are useful for development of a preparation for external application, such as a cosmetic. In each of the methods, an observation sample is used, which is prepared by staining all sweat glands, which are isolated alive, with a staining reagent, and then holding the all sweat glands on a support using at least one material selected from the group consisting of collagen, agarose, basement membrane matrix, poly-D-lysine and a membrane.

公开(公告)号：US20190049429A1

公开(公告)日：2019-02-14

申请号：US16085755

申请日：2017-07-18

Applicant: MANDOM CORPORATION ,  OSAKA UNIVERSITY

Inventor： Kie Nakashima ,  Ryuichiro Kurata ,  Fumitaka Fujita ,  Kiyotoshi Sekiguchi ,  Atsushi Tanemura ,  Hiroyuki Murota ,  Ichiro Katayama

IPC: G01N33/50 ,  A61B5/00

Abstract: A method for observing the dynamics of sweat glands and a method for evaluating a substance of interest, which are useful for development of a preparation for external application, such as a cosmetic. In each of the methods, an observation sample is used, which is prepared by staining all sweat glands, which are isolated alive, with a staining reagent, and then holding the all sweat glands on a support using at least one material selected from the group consisting of collagen, agarose, basement membrane matrix, poly-D-lysine and a membrane.

公开(公告)号：US10117857B2

公开(公告)日：2018-11-06

申请号：US15559322

申请日：2016-03-09

Applicant: OSAKA UNIVERSITY

Inventor： Mari Kaneda ,  Ichiro Katayama

IPC: A61K31/436 ,  A61K47/10 ,  A61K9/06 ,  A61P35/00

Abstract: An external medicine for diffuse plexiform neurofibromas is provided. The external medicine for diffuse plexiform neurofibromas in accordance with an embodiment of the present invention contains, as an active ingredient, at least one selected from the group consisting of sirolimus and sirolimus derivatives.